8.45
price up icon3.17%   0.26
after-market Handel nachbörslich: 8.45
loading

Cervomed Inc Aktie (CRVO) Neueste Nachrichten

pulisher
Dec 11, 2025

New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn

Dec 11, 2025
pulisher
Dec 10, 2025

Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance UK

Dec 10, 2025
pulisher
Dec 07, 2025

CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Dec 07, 2025
pulisher
Dec 05, 2025

Published on: 2025-12-06 11:12:10 - moha.gov.vn

Dec 05, 2025
pulisher
Dec 05, 2025

CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView

Dec 05, 2025
pulisher
Dec 05, 2025

Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus

Dec 05, 2025
pulisher
Dec 05, 2025

Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus

Dec 05, 2025
pulisher
Dec 04, 2025

CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed stock soars after promising dementia drug trial results - Investing.com

Dec 04, 2025
pulisher
Dec 04, 2025

CervoMed (NASDAQ: CRVO) Phase 2b shows 75% drop in DLB progression risk, eyes Phase 3 - Stock Titan

Dec 04, 2025
pulisher
Dec 04, 2025

How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com Canada

Dec 03, 2025
pulisher
Dec 03, 2025

CervoMed (NASDAQ:CRVO) Receives Buy Rating from D. Boral Capital - Defense World

Dec 03, 2025
pulisher
Dec 02, 2025

CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus

Dec 02, 2025
pulisher
Dec 02, 2025

CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus

Dec 02, 2025
pulisher
Dec 02, 2025

Neflamapimod reduces key neurodegeneration markers in DLB study - Investing.com

Dec 02, 2025
pulisher
Dec 02, 2025

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB) - marketscreener.com

Dec 02, 2025
pulisher
Dec 02, 2025

How CervoMed Inc. (DP8) stock gains from tech spending2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser

Dec 02, 2025
pulisher
Nov 27, 2025

What analyst consensus says on CervoMed Inc. stockRecession Risk & Free Fast Gain Swing Trade Alerts - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 26, 2025

CervoMed Inc. (CRVO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 26, 2025
pulisher
Nov 26, 2025

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - ADVFN

Nov 26, 2025
pulisher
Nov 26, 2025

CervoMed Inc Stock Analysis and ForecastVolume Profile Analysis & Explosive Profit Growth - earlytimes.in

Nov 26, 2025
pulisher
Nov 24, 2025

CervoMed Inc. to Present Phase 2b Trial Results of Neflamapimod for Dementia with Lewy Bodies at CTAD Conference - Quiver Quantitative

Nov 24, 2025
pulisher
Nov 24, 2025

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia With Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - 富途牛牛

Nov 24, 2025
pulisher
Nov 19, 2025

CervoMed Executives Make Bold Moves with Major Stock Purchases! - TipRanks

Nov 19, 2025
pulisher
Nov 19, 2025

Will CervoMed Inc. stock outperform Nasdaq indexWeekly Gains Summary & Free Technical Pattern Based Buy Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc. Stock (CRVO) Opinions on Insider Buying and Clinical Trial Progress - Quiver Quantitative

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc. stock retracement – recovery analysisChart Signals & Smart Money Movement Tracker - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will CervoMed Inc. (DP8) stock deliver compounding returns2025 Top Decliners & Verified Swing Trading Watchlist - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed Inc.: Chief commercial officer Winton buys $41k in CRVO - Investing.com Australia

Nov 19, 2025
pulisher
Nov 19, 2025

CervoMed CEO Alam buys shares worth $182,736 By Investing.com - Investing.com Australia

Nov 19, 2025
pulisher
Nov 19, 2025

Elder William buys CervoMed (CRVO) stock worth $29,250 By Investing.com - Investing.com Canada

Nov 19, 2025
pulisher
Nov 19, 2025

Insider Buying: Matthew Winton Acquires Additional Shares of Cer - GuruFocus

Nov 19, 2025
pulisher
Nov 19, 2025

Gregoire Sylvie buys CervoMed (CRVO) shares worth $182,736 By Investing.com - Investing.com Canada

Nov 19, 2025
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):